Browsing Category
Pharma Industry News
4743 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Will Merck’s Ohtuvayre pricing strategy face EU pushback during HTA reviews?
Will EU payers push back on Merck’s Ohtuvayre pricing? Find out how HTA reviews may shape COPD access, margins, and the drug’s long-term European rollout.
Emcure Pharmaceuticals gains on Sanofi India diabetes partnership, signaling deeper chronic care expansion
Emcure Pharmaceuticals partners with Sanofi India for exclusive oral anti-diabetic drug distribution, expanding diabetes care reach and boosting chronic portfolio.
Can CRENESSITY’s weight-loss benefit open doors for off-label interest in broader metabolic disorders?
Neurocrine Biosciences’ CRENESSITY shows weight-loss benefits in CAH—could this rare disease drug spark interest in obesity and insulin resistance care?
Is Ascletis Pharma quietly building an Asian obesity pipeline rival to Novo Nordisk and Eli Lilly?
Ascletis Pharma is building an obesity pipeline with ASC47 and ASC30. Can this dual-pathway approach rival Novo Nordisk and Eli Lilly?
Biocon secures FDA nod for Kirsty: Can the first interchangeable rapid-acting insulin aspart disrupt the US diabetes market?
Biocon Biologics wins FDA nod for Kirsty insulin, boosting Biocon shares. Can this $1.9B U.S. biosimilar opportunity reshape diabetes care?
Imugene’s A$37.5m capital raise fuels pivotal azer-cel trial plans as stock tumbles 17%
Imugene raises A$37.5M to fund pivotal azer-cel trial in 2026. Can its off-the-shelf CAR T therapy deliver on its $2B market promise?
Is Dr. Reddy’s oncology pipeline strong enough to compete with global innovators in 2025 and beyond?
Explore Dr. Reddy’s oncology pipeline, biosimilars approvals, and revenue outlook—can the Hyderabad-based pharma firm compete with global cancer drug innovators?
Neurocrine Biosciences’ one-year CAHtalyst phase 3 data shows sustained weight and insulin-resistance benefits in CAH patients
Neurocrine Biosciences’ CRENESSITY Phase 3 data shows strong weight and metabolic benefits in CAH—see what this means for NBIX stock and future sales.
Ascletis Pharma completes dosing in U.S. ASC47-semaglutide study for obesity treatment
Ascletis Pharma completes dosing in its ASC47-semaglutide obesity trial. Find out why Q4 2025 data could be a game changer for muscle-preserving weight loss.
Can fixed-dose combinations make Ohtuvayre Merck’s next billion-dollar respiratory franchise?
Can a fixed-dose combo turn Ohtuvayre into Merck’s next billion-dollar COPD franchise? Find out how lifecycle strategy may reshape respiratory care.